股本结构
单位：万股
| 公告日期 | 2022-11-10 | 2022-09-29 | 2022-08-12 | 2022-03-11 | 2021-11-12 | 2021-11-12 |
|---|---|---|---|---|---|---|
| 证券总股本 | 2913.77 | 2913.77 | 2817.25 | 2753.92 | 2753.71 | 2747.70 |
| 普通股本 | 2913.77 | 2913.77 | 2817.25 | 2753.92 | 2753.71 | 2747.70 |
| 优先股 | 1.50 | 未披露 | 1.50 | 1.50 | 未披露 | 1.50 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2022-09-30 | 2022-09-19 | 2022-06-30 | 2021-12-31 | 2021-11-09 | 2021-09-30 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2022-11-10 | 2913.77 | 1.50 |
更多>>
From June 30, 2022 to September 30, 2022
Common shares issued
|
2022-09-30 |
| 2022-09-29 | 2913.77 | 未披露 | 定期报告 | 2022-09-19 |
| 2022-08-12 | 2817.25 | 1.50 |
更多>>
From March 31, 2022 to June 30, 2022
Common shares issued
|
2022-06-30 |
| 2022-03-11 | 2753.92 | 1.50 |
更多>>
From December 31, 2020 to December 31, 2021
Issuance of common stock, net of issuance costs
Exercise of Warrants
Settlement of dividends on Preferred Stock with adjustment of conversion price
Conversion of Preferred Stock
|
2021-12-31 |
| 2021-11-12 | 2753.71 | 未披露 | 定期报告 | 2021-11-09 |
| 2021-11-12 | 2747.70 | 1.50 |
更多>>
From June 30, 2021 to September 30, 2021
Issuance of common stock, net of issuance costs
Exercise of Warrants
|
2021-09-30 |
| 2021-10-05 | 2742.70 | 未披露 | 定期报告 | 2021-09-20 |
| 2021-08-06 | 2689.03 | 1.50 | 定期报告 | 2021-08-03 |
| 2021-08-06 | 2614.50 | 1.50 |
更多>>
From March 31, 2021 to June 30, 2021
Conversion of Preferred Stock to Common Stock
Exercise of Warrants
|
2021-06-30 |
| 2021-04-30 | 2284.01 | 未披露 | 定期报告 | 2021-04-27 |
| 2021-05-14 | 2283.63 | 未披露 |
更多>>
From December 31, 2020 To March 31, 2021
Public offering
|
2021-03-31 |
| 2021-03-05 | 2178.66 | 未披露 |
更多>>
1.Common stock offered by the company 7,875,000 shares.
2.The number of shares of common stock to be outstanding after this offering is based on the actual number of shares outstanding as of December 31, 2020, which was 13,911,633 shares.
|
2021-03-05 |
| 2021-03-12 | 1391.16 | 2.30 |
更多>>
from December 31, 2019 to December 31, 2020
Issuance of Series B Preferred Stock, net of issuance costs
Private placement of common stock and warrants
|
2020-12-31 |
| 2020-12-21 | 1391.16 | 未披露 | 定期报告 | 2020-12-21 |
| 2020-11-13 | 915.63 | 2.30 |
更多>>
From June 30, 2020 to September 30, 2020
Series B Preferred Stock issuance costs
|
2020-09-30 |
| 2020-06-30 | 915.63 | 2.30 | 定期报告 | 2020-06-25 |
| 2020-03-13 | 915.63 | 1.50 |
更多>>
From December 31, 2018 to December 31, 2019
Issuance of Series A Preferred Stock, net of issuance costs
Common shares issued to vendor
Common shares issued, net of issuance costs
|
2019-12-31 |
| 2019-11-08 | 915.19 | 未披露 | 定期报告 | 2019-11-06 |
| 2019-11-08 | 912.30 | 1.50 |
更多>>
from June 30, 2019 to September 30, 2019
Common shares issued to vendor
Common shares issued for cash
|
2019-09-30 |
| 2019-08-09 | 904.43 | 未披露 | 定期报告 | 2019-08-07 |
| 2019-08-09 | 887.14 | 1.50 |
更多>>
from March 31, 2019 to June 30,2019
Common shares issued to vendor
Common shares issued, net of issuance costs - ATM
|
2019-06-30 |
| 2019-07-02 | 887.14 | 未披露 | 定期报告 | 2019-06-28 |
| 2019-05-10 | 875.36 | 未披露 | 定期报告 | 2019-05-01 |
| 2019-05-10 | 875.22 | 1.50 |
更多>>
From December 31, 2018 to March 31, 2019
Common shares issued to vendor
Issuance of Series A Preferred Stock, net of issuance costs
|
2019-03-31 |
| 2019-03-27 | 875.22 | 1.50 | 定期报告 | 2019-03-25 |
| 2019-03-25 | 875.06 | 1.50 | 定期报告 | 2019-03-01 |
| 2019-01-10 | 874.92 | 未披露 | 定期报告 | 2019-01-08 |
| 2019-03-08 | 874.40 | 未披露 |
更多>>
from December 31, 2017 to December 31, 2018
Common shares issued to vendor
|
2018-12-31 |
| 2018-11-09 | 874.21 | 未披露 | 定期报告 | 2018-11-01 |
| 2018-11-09 | 873.82 | 未披露 | 定期报告 | 2018-09-30 |
| 2018-08-10 | 873.59 | 未披露 | 定期报告 | 2018-08-01 |
| 2018-08-10 | 873.18 | 未披露 | 定期报告 | 2018-06-30 |
| 2018-05-11 | 873.00 | 未披露 | 定期报告 | 2018-05-04 |
| 2018-04-27 | 872.82 | 未披露 | 定期报告 | 2018-04-23 |
| 2018-05-11 | 872.62 | 未披露 | 定期报告 | 2018-03-31 |
| 2018-03-23 | 872.51 | 未披露 | 定期报告 | 2018-03-01 |
| 2018-03-23 | 872.28 | 未披露 |
更多>>
from December 31, 2016 to December 31, 2017
Stock-based compensation expense
Conversion of convertible debt
Effect of reverse merger
Offering of common stock and warrants
Common shares issued to vendor
|
2017-12-31 |
| 2017-11-09 | 872.17 | 未披露 | 定期报告 | 2017-11-03 |
| 2017-11-09 | 871.95 | 未披露 |
更多>>
From December 31,2016 To September 30, 2017
Stock-based compensation expense
Conversion of convertible debt
Effect of reverse merger
Offering of common stock and warrants
Common shares issued to vendor
|
2017-09-30 |
| 2017-08-11 | 868.84 | 未披露 | 定期报告 | 2017-08-09 |
| 2017-08-11 | 868.60 | 未披露 |
更多>>
From December 31, 2016 to June 30, 2017
Conversion of convertible debt
Effect of reverse merger
Offering of common stock and warrants
Common shares issued to vendor
|
2017-06-30 |
| 2017-04-20 | 603.78 | 未披露 |
更多>>
On April 19, 2017, PLx Pharma Inc. effected a 1-for-8 reverse stock split of its common stock. For the common stock to begin tradingon The NASDAQ Capital Market on a post-split basis, under the symbol “PLXP” beginning on April 20, 2017.
|
2017-04-20 |
| 2015-08-12 | 1026.95 | 未披露 |
更多>>
from December 31, 2014 to June 30, 2015
Share-Based payment to vendors
Share-Based compensation
Cashless Exercise of Warrants
Issuance of Common Stock, net of issuance costs
|
2015-06-30 |
| 2015-10-05 | 424.11 | 1754.77 | 定期报告 | 2015-06-30 |
| 2015-05-13 | 856.60 | 未披露 | 定期报告 | 2015-05-13 |
| 2015-05-13 | 856.47 | 未披露 |
更多>>
from December 31, 2014 to March 15, 2015
Share-Based payment to vendors
Share-Based compensation
|
2015-03-15 |
| 2015-03-23 | 853.83 | 未披露 |
更多>>
from December 31, 2013 to December 31, 2014
Issuance of Restricted Membership Interest Awards
Issuance of Restricted Membership Interest to Vendors
Issuance of Membership Interest for Warrant Conversion
Corporate Conversion
Initial Public Offering, Net of Issuance Costs
Cashless Exercise of Warrants
|
2014-12-31 |
| 2014-05-12 | 853.79 | 未披露 |
更多>>
from December 31, 2013 to March 31, 2014
Corporate Conversion
Initial Public Offering, net of issuance costs
|
2014-03-31 |
| 2014-03-13 | 812.54 | 未披露 | 定期报告 | 2014-03-13 |
| 2014-02-24 | 73.56 | 未披露 |
更多>>
from December 31,2012 to December 31,2013
Private Placement Offerings at $50 per unit, net of issuance costs
Executive Compensation settled with Membership Interests
Issuance of Restricted Membership Interest Awards
Issuance of Restricted Membership Interest to Vendors
|
2013-12-31 |
From June 30, 2022 to September 30, 2022
Common shares issued
From March 31, 2022 to June 30, 2022
Common shares issued
From December 31, 2020 to December 31, 2021
Issuance of common stock, net of issuance costs
Exercise of Warrants
Settlement of dividends on Preferred Stock with adjustment of conversion price
Conversion of Preferred Stock
From June 30, 2021 to September 30, 2021
Issuance of common stock, net of issuance costs
Exercise of Warrants
From March 31, 2021 to June 30, 2021
Conversion of Preferred Stock to Common Stock
Exercise of Warrants
From December 31, 2020 To March 31, 2021
Public offering
1.Common stock offered by the company 7,875,000 shares.
2.The number of shares of common stock to be outstanding after this offering is based on the actual number of shares outstanding as of December 31, 2020, which was 13,911,633 shares.
from December 31, 2019 to December 31, 2020
Issuance of Series B Preferred Stock, net of issuance costs
Private placement of common stock and warrants
From June 30, 2020 to September 30, 2020
Series B Preferred Stock issuance costs
From December 31, 2018 to December 31, 2019
Issuance of Series A Preferred Stock, net of issuance costs
Common shares issued to vendor
Common shares issued, net of issuance costs
from June 30, 2019 to September 30, 2019
Common shares issued to vendor
Common shares issued for cash
from March 31, 2019 to June 30,2019
Common shares issued to vendor
Common shares issued, net of issuance costs - ATM
From December 31, 2018 to March 31, 2019
Common shares issued to vendor
Issuance of Series A Preferred Stock, net of issuance costs
from December 31, 2017 to December 31, 2018
Common shares issued to vendor
from December 31, 2016 to December 31, 2017
Stock-based compensation expense
Conversion of convertible debt
Effect of reverse merger
Offering of common stock and warrants
Common shares issued to vendor
From December 31,2016 To September 30, 2017
Stock-based compensation expense
Conversion of convertible debt
Effect of reverse merger
Offering of common stock and warrants
Common shares issued to vendor
From December 31, 2016 to June 30, 2017
Conversion of convertible debt
Effect of reverse merger
Offering of common stock and warrants
Common shares issued to vendor
On April 19, 2017, PLx Pharma Inc. effected a 1-for-8 reverse stock split of its common stock. For the common stock to begin tradingon The NASDAQ Capital Market on a post-split basis, under the symbol “PLXP” beginning on April 20, 2017.
from December 31, 2014 to June 30, 2015
Share-Based payment to vendors
Share-Based compensation
Cashless Exercise of Warrants
Issuance of Common Stock, net of issuance costs
from December 31, 2014 to March 15, 2015
Share-Based payment to vendors
Share-Based compensation
from December 31, 2013 to December 31, 2014
Issuance of Restricted Membership Interest Awards
Issuance of Restricted Membership Interest to Vendors
Issuance of Membership Interest for Warrant Conversion
Corporate Conversion
Initial Public Offering, Net of Issuance Costs
Cashless Exercise of Warrants
from December 31, 2013 to March 31, 2014
Corporate Conversion
Initial Public Offering, net of issuance costs
from December 31,2012 to December 31,2013
Private Placement Offerings at $50 per unit, net of issuance costs
Executive Compensation settled with Membership Interests
Issuance of Restricted Membership Interest Awards
Issuance of Restricted Membership Interest to Vendors